BioCentury
ARTICLE | Company News

Azure Biotech Inc., Ethicor Pharma, Ligand deal

July 29, 2013 7:00 AM UTC

Ligand granted newco Azure an exclusive, worldwide license to develop and commercialize a new formulation of Ligand's osteoporosis drug lasofoxifene for an undisclosed women's health indication. Ligand is eligible to receive $2.7 million in development and regulatory milestones, plus 5% royalties on sales. Ligand declined to disclose details.

Separately, Ligand granted Ethicor exclusive rights to develop and commercialize oral lasofoxifene in the European Economic Area, Switzerland, India, Pakistan and Bangladesh. Ligand is eligible for sales milestones, plus double-digit royalties. The partners declined to provide details. ...